SynthesisMedicine2017
A systematic review and meta-analysis of the prevalence of norovirus in cases of gastroenteritis in developing countries.
Synthesis in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 5 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Epidemiology of norovirus infection in Nigeria: a systematic review and meta-analysis.Archives of virology · 2024Pooled it
- Human adenoviruses in children with gastroenteritis: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Global prevalence of norovirus gastroenteritis after emergence of the GII.4 Sydney 2012 variant: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Pooled prevalence and genetic diversity of norovirus in Africa: a systematic review and meta-analysis.Virology journal · 2022Pooled it
- Global Status of Bufavirus, Cosavirus, and Saffold Virus in Gastroenteritis: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Safety, tolerability and immunogenicity of a quadrivalent recombinant norovirus vaccine (Pichia pastoris) in participants six weeks of age or older: Phase I/IIa trial.Emerging microbes & infections · 2025Trial
- Effect of Non-Rotavirus Enteric Infections on Vaccine Efficacy in a ROTASIIL Clinical Trial.The American journal of tropical medicine and hygiene · 2024Trial
- Prevalence of astrovirus-associated gastroenteritis among hospitalized pediatric patients in Asia: A systematic review and meta-analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Infectious Causes of Acute Febrile Illness in Belize, 2020-2022.The American journal of tropical medicine and hygiene · 2026Article
- Epidemiological pattern and incidence estimation of infectious diarrhea before the COVID-19 pandemic: Beijing, China, 2015-2019.Frontiers in public health · 2026Article
- Infectious disease risk after the October 2024 flash flood in Valencia, Spain: Disaster evolution, strategic scenario analysis, and extrapolative baseline for a One Health assessment.One health (Amsterdam, Netherlands) · 2025Article
- CVID Enteropathy Associated With Chronic Norovirus Infection: Background, Clinical Features, and Therapeutic Aspects.Reviews in medical virology · 2025Review
- An unusual diarrheal outbreak in the community in Eastern Thailand caused by Norovirus GII.3[P25].Virology journal · 2024Article
- The Impact of Norovirus on Children and Adolescents: Implications for Ongoing Vaccine Development.Current pediatrics reports · 2024Review
- Article
- Effects of Probiotics in Adults with Gastroenteritis: A Systematic Review and Meta-Analysis of Clinical Trials.Diseases (Basel, Switzerland) · 2023Review
- Norovirus infection among HIV-infected patients in Abuja, Nigeria: impact of combination antiretroviral therapy status.BMC infectious diseases · 2023Article
- Article
- Spatio-temporal distribution and influencing factors of norovirus outbreaks in Beijing, China from 2016 to 2020.BMC infectious diseases · 2023Article
- Evaluation of the transmissibility of norovirus and the effectiveness of prevention and control measures for schools in Jiangsu Province.Annals of medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile norovirus (NoV) is well known as a leading causal pathogen for acute gastroenteritis in developed countries,structured data on prevalence in developing countries are not available thus far. This review aims to estimate the prevalence of NoV in cases of gastroenteritis in developing countries based on recently published reports.
methodsRelevant studies were identified by searching PubMed and Web of Science for the period January 1, 1990 through March 31, 2016. We included studies performed in developing countries with a study period of at least 12 months and which provided information on polymerase chain reaction (PCR)-confirmed NoV prevalence in patients diagnosed with acute gastroenteritis. A metaanalysis was conducted on NoV prevalence, focused on viral genogroups GI and GII, in cases of acute gastroenteritis.
resultsUsing evidence from 178 articles, the estimated NoV prevalence among 148,867 patients with acute gastroenteritis was 17% (95% confidence interval [CI]: 15-18%). The prevalence decreased from 18% (95% CI: 16-20%) for upper middle-income countries to 15% (13-18%) and 6% (3-10%) for lower middle- and low-income countries, respectively. There were no significant differences in NoV prevalence by age group (under 5 years, 5 years and over, and mixed ages) or severity of symptoms as defined by community, outpatient, or inpatient setting. The pooled prevalence of NoV GII (15%, 95% CI: 13-17%) was significantly higher than that of NoV GI (1%, 95% CI: 1-1%) in patients with acute gastroenteritis.
conclusionFrom the evidence considered in this review, the estimated prevalence of NoV in patients with acute gastroenteritis in developing countries was 17%. This estimate can be used to evaluate the burden of NoV-associated acute gastroenteritis in developing countries, which is currently unclear due to poor diagnosis and surveillance systems, and the estimation may enhance the development of human NoV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.